Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Initial Therapy”

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07219459
What this trial is testing

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Who this might be right for
Unresectable or Metastatic Hepatocellular CarcinomaChild-Pugh A Hepatocellular CarcinomaFailure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
CatalYm GmbH 104
Testing effectiveness (Phase 2)Enrolling By InvitationNCT07376629
What this trial is testing

HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Who this might be right for
TNBC
Huabo Biopharm Co., Ltd. 60
Testing effectiveness (Phase 2)Looking for participantsNCT05173246
What this trial is testing

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Who this might be right for
Esophageal Small Cell Carcinoma
Sun Yat-sen University 43
Not applicableLooking for participantsNCT06813573
What this trial is testing

Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma

Who this might be right for
Follicular LymphomaDiffuse Large B-Cell Lymphoma
Gustave Roussy, Cancer Campus, Grand Paris 50
Large-scale testing (Phase 3)UnknownNCT04033354
What this trial is testing

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Who this might be right for
Squamous Non Small Cell Lung Cancer
Shanghai Henlius Biotech 537
Testing effectiveness (Phase 2)Study completedNCT04391556
What this trial is testing

Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma

Who this might be right for
Prostate Adenocarcinoma
Centre Leon Berard 57
Post-approval studies (Phase 4)Study completedNCT03093480
What this trial is testing

Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Who this might be right for
Hemophilia A With Inhibitors
Bioverativ, a Sanofi company 16
Testing effectiveness (Phase 2)Ended earlyNCT00977561
What this trial is testing

Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Carcinoma
Pfizer 9
Post-approval studies (Phase 4)Ended earlyNCT00129870
What this trial is testing

CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Sanofi 180
Not applicableStudy completedNCT05452954
What this trial is testing

Psychosocial ADHD Interventions - Brief Parent Training

Who this might be right for
ADHDADHD - Combined TypeADHD Predominantly Inattentive Type+7 more
Accare 28
Testing effectiveness (Phase 2)Ended earlyNCT03559049
What this trial is testing

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Stage IV Non-small Cell Lung Cancer
University of Michigan Rogel Cancer Center 25
Not applicableUnknownNCT02642458
What this trial is testing

Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients

Who this might be right for
Metastatic Breast Cancer
University Hospital Tuebingen 300
Not applicableUnknownNCT01182259
What this trial is testing

The Incidence and Risk Factors of Side Effects During the Initial Phase of Rifater Therapy - a Prospective Study

Who this might be right for
Tuberculosis
E-DA Hospital 200
Not applicableNot Yet RecruitingNCT07618780
What this trial is testing

Stereotactic Radioablation as First-Line Therapy for Scar-Related Ventricular Tachycardia

Who this might be right for
Ventricular Tachycardia, MonomorphicCardiomyopathies
Southlake Health 20
Not applicableStudy completedNCT03107169
What this trial is testing

Treatment of Initial Clostridium Difficile Infection

Who this might be right for
Clostridium Difficile Infection
Universidad Autonoma de Nuevo Leon 10
Very early researchStudy completedNCT05880862
What this trial is testing

Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls

Who this might be right for
Urinary Bladder, OveractiveUrinary IncontinenceAccidental Falls
The University of Texas Medical Branch, Galveston 48
Large-scale testing (Phase 3)Study completedNCT00492986
What this trial is testing

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Who this might be right for
Carcinoma, Renal Cell
Bayer 1,150
Testing effectiveness (Phase 2)UnknownNCT05189483
What this trial is testing

Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.

Who this might be right for
Soft Tissue Sarcoma
Henan Cancer Hospital 40
Testing effectiveness (Phase 2)Study completedNCT03101566
What this trial is testing

Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer

Who this might be right for
Biliary Tract Neoplasms
University of Michigan Rogel Cancer Center 75
Not applicableStudy completedNCT04667988
What this trial is testing

JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis

Who this might be right for
Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression
Mansoura University 76
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation